Linked Life Data

16904054

Source:http://linkedlifedata.com/resource/pubmed/id/16904054

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-8-14
pubmed:abstractText
The survival benefit demonstrated by docetaxel-based therapy in two randomized trials, Southwest Oncology Group (SWOG) 99-16 and TAX 327, has changed the perception of chemotherapy in men with hormone-refractory prostate cancer from nihilism to optimism. These survival improvements are of similar magnitude to those found in trials that established chemotherapeutic regimens for metastatic breast, lung, or colorectal cancer. The timing of chemotherapy in the aforementioned solid tumors is much more clearly defined than in men with metastatic prostate cancer. Traditionally, chemotherapy in men with hormone-resistant prostate cancer was reserved for symptomatic patients only; the inclusion of symptomatic and asymptomatic patients in SWOG 99-16 and TAX 327 has raised several questions regarding the optimal use of chemotherapy in these patients. When is the best time to initiate docetaxel-based chemotherapy? Is it appropriate to use chemotherapy in high-risk patients as adjuvant therapy? Although retrospective analysis of current trials may provide hypothesis, only properly designed randomized clinical trials will answer these questions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1527-2729
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
370-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Cytotoxic chemotherapy for prostate cancer: Who and when?
pubmed:affiliation
Department of Hematology and Oncology, Columbia University, 161 Ft. Washington Avenue, New York, NY 10032, USA.
pubmed:publicationType
Journal Article, Review